A. Schirizzi

Variations in Circulating Levels of Angiopoietin-2 Over Time Are Predictive of Ramucirumab–Paclitaxel Therapy Outcome in Advanced Gastric Cancer: Results of Prospective Study

G. Giannelli, R. D'Alessandro, M. G. Refolo, 2022, Frontiers in Oncology.

The multiple combination of Paclitaxel, Ramucirumab and Elacridar reverses the paclitaxel-mediated resistance in gastric cancer cell lines

G. Giannelli, J. Kopecka, C. Riganti, 2023, Frontiers in Oncology.

Targeting Angiogenesis in the Era of Biliary Tract Cancer Immunotherapy: Biological Rationale, Clinical Implications, and Future Research Avenues

G. Giannelli, R. D'Alessandro, A. Ricci, 2023, Cancers.

Durvalumab in advanced cholangiocarcinoma: is someone knocking down the door?

G. Giannelli, R. D'Alessandro, A. Ricci, 2023, Immunotherapy.

VEGFA Status as a Predictive Marker of Therapy Outcome in Metastatic Gastric Cancer Patients Following Ramucirumab-Based Treatment

G. Giannelli, A. Valentini, D. Tolomeo, 2023, Biomedicines.

Autotaxin–Lysophosphatidate Axis: Promoter of Cancer Development and Possible Therapeutic Implications

G. Giannelli, A. Ricci, C. Lotesoriere, 2024, International journal of molecular sciences.